Foghorn to host conference call and webcast on pipeline of potential first-in-class medicines in conjunction with the 2024 aacr annual meeting

Company management will review key pipeline programs, including an update on fhd-286 for aml, new preclinical data for the brm selective inhibitor fhd-909 and for its selective cbp and ep300 degrader programs

FHTX Ratings Summary

FHTX Quant Ranking